Welcome to our dedicated page for OKYO Pharma Ordinary Shares news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO Pharma Ordinary Shares stock.
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for inflammatory eye diseases and chronic pain conditions. The company is at the forefront of creating innovative treatments for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP), both of which represent significant unmet medical needs in the ophthalmology sector.
One of OKYO Pharma's hallmark achievements is its development of the OK-101 ophthalmic solution. This drug candidate has shown promising results in pre-clinical studies, demonstrating dual-action anti-inflammatory and neuropathic corneal pain-reducing activities. The ongoing Phase 2 clinical trials are aimed at establishing the safety and efficacy of OK-101 in treating DED and NCP. Notably, these trials have successfully completed patient enrollment, with top-line results expected soon.
OKYO Pharma's approach leverages a unique membrane-anchored-peptide technology to ensure the prolonged presence of the drug in the ocular environment, thereby enhancing its therapeutic impact. In recent studies, OK-101 has exhibited statistically significant improvements in multiple dry eye-related symptoms, including stinging, burning, and blurred vision, as well as a notable reduction in conjunctival staining. These promising outcomes pave the way for future Phase 3 registration trials.
Financially, OKYO Pharma is well-positioned, with its ordinary shares listed on the NASDAQ Capital Market. The company continues to forge strategic partnerships and collaborations to bolster its research and development efforts. With a robust pipeline and a commitment to addressing the complex biology of eye diseases, OKYO Pharma stands as a pioneering entity in the biopharmaceutical landscape.
The latest developments include positive safety and efficacy results from the Phase 2 trials of OK-101, and the recent FDA clearance for OK-101's Investigational New Drug (IND) application for treating NCP. These milestones underscore the potential of OKYO Pharma's innovative solutions to significantly improve patient outcomes.
OKYO Pharma Limited (NASDAQ: OKYO) announced its CEO, Dr. Gary Jacob, will be featured on The RedChip Money Report on Bloomberg TV on September 10, 2022. The interview will cover the company's NASDAQ listing, plans for a Phase 2 study for Dry Eye Disease, and expectations for top-line data. This access expands OKYO's visibility as it operates in the biotechnology sector, focusing on new treatments for inflammatory dry eye diseases and ocular pain.
OKYO Pharma Limited (NASDAQ: OKYO) announced an upcoming interview with CEO Dr. Gary Jacob on the RedChip Money Report airing on Bloomberg TV on September 10, 2022, at 7 p.m. ET. The interview will cover the company's NASDAQ listing and plans for a Phase 2 study for Dry Eye Disease, including anticipated top-line data. OKYO focuses on developing novel treatments for inflammatory dry eye diseases and chronic pain, and is listed on both NASDAQ and the London Stock Exchange.
On September 7, 2022, OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that all resolutions at its Annual General Meeting were successfully passed. The voting results showed overwhelming support, with key resolutions such as the approval of the report and accounts receiving 99.99852% approval. Shareholders, totaling 1,415,040,468 ordinary shares, participated actively in the voting process. The resolutions included the re-election of directors and the appointment of auditors, reflecting strong governance practices and shareholder confidence in the company's direction.
OKYO Pharma Limited is gearing up for a Q4 2022 IND filing for OK-101, targeting dry eye disease (DED) and supported by AmbioPharm. Following a successful pre-IND meeting with the FDA in Q1 2022, the Phase 2 trial is set to commence in Q1 2023, designed to expedite market entry. OK-101, a lipid-peptide analog, showcases potent anti-inflammatory properties in animal models, addressing a significant unmet need in the multibillion-dollar DED market.
OKYO Pharma Limited (NASDAQ: OKYO) announced its audited results for the year ending March 31, 2022. They reported a comprehensive loss of £3,976k and a cash balance of £2,056k. The company is advancing its lead candidate OK-101 for dry eye disease (DED) and plans to file an IND by Q4 2022, followed by a Phase 2 trial in early 2023. Preclinical studies showed significant efficacy for OK-101 in reducing corneal permeability and pain, with potential future evaluations for uveitis and allergic conjunctivitis.
On June 9, 2022, OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that non-executive director Willy Simon acquired 361,195 ordinary shares at prices ranging from £0.02679 to £0.0284 each. This market purchase indicates Simon's confidence in the company's growth potential in the dry eye care sector. OKYO Pharma is focused on developing novel treatments for dry eye diseases and ocular pain, with its lead candidate, OK-101, demonstrating promising anti-inflammatory effects in preclinical studies.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that Panetta Partners Limited acquired 5,800,000 ordinary shares at £0.0625 each on May 19, 2022. This purchase increases Gabriele Cerrone's beneficial interest from 39.64% to 40.06%. However, dilution from a recent offering reduces his holdings to 39.08%. The company's focus on developing novel molecules for treating inflammatory dry eye diseases remains ongoing, highlighting its commitment to addressing significant medical needs in the eye care market.
OKYO Pharma announced the closing of its public offering of 625,000 American Depository Shares (ADSs) at $4.00 per share, totaling $2.5 million in gross proceeds. The funds will be utilized to advance the IND filing for OK-101 to treat dry eye disease (DED), support an initial Phase 2 clinical trial, and for general corporate purposes. ThinkEquity served as the sole book-running manager. This offering follows the effective registration statement filed with the SEC on May 16, 2022.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 25,000 American Depository Shares (ADS) at $3.8749 each on May 17, 2022. This transaction increased Cerrone's beneficial interest from 39.52% to 39.64%. However, with an upcoming offering closing on May 19, 2022, his stake will be diluted to 38.50%. The ADS represents 65 ordinary shares, and the transaction occurred on NASDAQ.
OKYO Pharma Limited has announced the pricing of its underwritten initial public offering (IPO) of American Depositary Shares (ADSs) on the Nasdaq Capital Market. The company will issue 625,000 ADSs at $4.00 each, raising approximately $2.5 million in gross proceeds. The offering is expected to close on May 19, 2022. Funds will be used for advancing clinical trials and general corporate needs. The total number of Ordinary Shares after the offering will reach 1,415,040,468.
FAQ
What is the current stock price of OKYO Pharma Ordinary Shares (OKYO)?
What is the market cap of OKYO Pharma Ordinary Shares (OKYO)?
What is OKYO Pharma Limited known for?
What are the key products of OKYO Pharma?
What recent achievements has OKYO Pharma accomplished?
What is the significance of OK-101 in the treatment of Dry Eye Disease?
How is OKYO Pharma's financial condition?
What are the future plans for OK-101?
What is Dry Eye Disease (DED)?
What is Neuropathic Corneal Pain (NCP)?
How does OK-101 work?
Where can I find more information about OKYO Pharma?
